Drug Details
General Information of the Drug (ID: DR7409) | ||||
---|---|---|---|---|
Name |
Rituximab
|
|||
Molecular Type |
Antibody
|
|||
Disease | Acute lymphoblastic leukemia [ICD-11: 2B33] | Approved | [1] | |
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Vincristine | Catharanthus roseus | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Biological
Regulation |
Increase | Tumor cell death | ||||
In-vitro Model | Ramos | CVCL_0597 | Burkitt lymphoma | Homo sapiens | ||
Experimental
Result(s) |
Rituximab synergizes with vincristine in the killing of Ramos Burkitt's lymphoma B cell line. | |||||
Pentostatin + Cladribine | Click to Show/Hide the Molecular Data of This NP | |||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Experimental
Result(s) |
The combination of a purine analog with rituximab was safe and effective for patients with recurrent HCL. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Leukocyte surface antigen Leu-16 (CD20) | Molecule Info | [4] | |
KEGG Pathway | Hematopoietic cell lineage | Click to Show/Hide |